17 results about "Methylcobalamin" patented technology

Disclosed are pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and methylcobalamin. Also disclosed are methods of using the pharmaceutical compositions to treat patients suffering from Alzheimer's disease or Parkinson's disease.

The application provides a kind of medicine composition for treating muscle and bone disease and its application, belong to medical technology field.The medicine composition includes the following weight parts components: compound angelica injection 5-10 parts, kadsura injection 5-10 parts, wild medlar injection 5-10 parts, methylcobalamin injection 5-10 parts;It can also be selectively added vitamin B1 injection, vitamin B12 injection, yellow Chinese wax injection or bone peptide injection.The composition of the application is administered by acupoint injection or intramuscular injection, utilizes the synergistic effect of multiple traditional Chinese medicine injection and western medicine injection, reaches the comprehensive treatment effect of promoting blood circulation to remove blood stasis, dispelling wind to stop pain, nerve nutrition.Clinical experiments show that the application has significant effect on lumbar disc herniation, cervical spondylosis, shoulder periarthritis, knee osteoarthritis, femoral head necrosis, osteoporosis and the like, and the total effective rate is more than 95%, with fast effect, low recurrence rate, and no hormone-related side effects, suitable for patients of all ages.

This invention relates to the field of pharmaceutical analysis and detection technology, and proposes a method for detecting related substances in methylcobalamin tablets. The method employs reversed-phase high-performance liquid chromatography (RP-HPLC) with an ultraviolet (UV) detector. The chromatographic conditions of the RHPLC-UV detector method include: mobile phases A and B; mobile phase A is a 92:8 mixture of potassium dihydrogen phosphate solution and acetonitrile, and mobile phase B is a 92:8 mixture of acetonitrile and water; gradient elution is used. This technical solution solves the problem of inaccurate detection of related substances in methylcobalamin tablets in related technologies.

This invention discloses a strain of *Lactobacillus paracasei* capable of converting cyanocobalamin and promoting its absorption, thereby enhancing brain nerve repair and improving cognition, and its postbiotic, belonging to the fields of microbial technology and pharmaceutical technology. The *Lactobacillus paracasei* CCFM1527 and its prepared postbiotic provided by this invention promote the growth of vitamin B1 in the host. 12 The neuroprotective effects of upregulating the expression of absorption receptors and converting CN-CbI to methylcobalamin include: (1) promoting the upregulation of Amnionless expression in intestinal cells (Caco-2); (2) converting CN-CbI to methylcobalamin; and (3) promoting the upregulation of Amnionless expression in mouse ileum. AMN Upregulation of gene expression (4) significantly increased the levels of vitamin B in mice. 12 (5) Significantly promotes the expression of MBP and PSD-95 proteins in mice; (6) Improves the decline in cognitive ability in mice, and has great application prospects.

This invention provides a pharmaceutical composition combining azelastine and methylcobalamin. [Solution] An orally administered pharmaceutical composition is provided, comprising azelastine or a pharmaceutically acceptable salt of azelastine, methylcobalamin, and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition is formulated as a capsule, caplet, tablet, or pill configured for oral administration and absorption in the gastrointestinal tract, and the azelastine or a pharmaceutically acceptable salt of azelastine and methylcobalamin are present together in the pharmaceutical composition in a therapeutically effective daily dose for treating Alzheimer's disease or Parkinson's disease in human patients.

The present invention provides a novel food and drink containing at least one cobalamin selected from the group consisting of cyanocobalamin, hydroxocobalamin, adenosylcobalamin, methylcobalamin, and sulfitocobalamin. According to an embodiment of the present invention, there is provided a bottled beverage containing carnosine and at least one cobalamin selected from the group consisting of cyanocobalamin, hydroxocobalamin, adenosylcobalamin, methylcobalamin, and sulfitocobalamin, wherein the content of carnosine is 0.70-15 mg / mL and the content of the at least one cobalamin is 0.005-1 µm / mL.

The invention relates to the technical field of medicine detection equipment, and discloses a mecobalamin tablet production line multi-station synchronous quality detection device which comprises a discharging structure, a detection structure, a plurality of feeding structures and a plurality of discharging structures. The detection structure is arranged on the right side of the discharging structure, the multiple feeding structures are arranged on the right side of the detection structure at equal intervals and symmetrically located on the front side and the rear side of the detection structure correspondingly, and the multiple discharging structures are arranged on the feeding frame structure correspondingly. Multi-station synchronous double-face detection is achieved, the detection efficiency and the coverage rate are greatly improved, directional screening and collecting are achieved, accurate separation of qualified products and unqualified products is achieved, a conveying structure can be flexibly adjusted, and the space utilization rate and the equipment layout reasonability are improved; accessories can be flexibly replaced, the adaptability and the generalization degree of equipment are greatly improved, full-process automatic operation is achieved, and manual intervention and the equipment failure rate are reduced.

This invention discloses a sustained-release membrane for postoperative treatment of diabetic peripheral neuropathy and its preparation method. The sustained-release membrane comprises, from the outside in, a PLGA nanofiber outer layer containing tacrolimus and magnesium hydroxide nanoparticles, a glucose-responsive hydrogel middle layer containing insulin and glucose oxidase / catalase, and a PCL-oriented nanofiber inner layer containing methylcobalamin. The layers are connected by a polydopamine interface layer, and the outermost surface of the outer layer is coated with a hyaluronic acid anti-adhesion coating. Insulin, as a local neurotrophic factor, directly activates the PI3K / Akt / mTOR and ERK / MAPK signaling pathways, promoting axonal regeneration and myelin repair. The sustained-release membrane integrates three major functions: immunomodulation / anti-inflammation, glucose-responsive insulin neurotrophic delivery, and sustained nerve regeneration promotion. It prevents postoperative nerve re-adhesion through a spatiotemporal sequential drug release strategy. All components are biodegradable and do not require secondary surgery for removal.

The invention provides an enteric-coated tablet for treating neuritis and a preparation method of the enteric-coated tablet. The enteric-coated tablet is prepared from the following components in percentage by weight: 0.01%-1% of mecobalamin, 60%-80% of butanedisulfonic acid adenosyl methionine, 10%-30% of a diluent, 4%-9% of an adhesive, 1%-5% of a disintegrating agent, 0.1%-1% of a lubricant and 8%-16% of an enteric-coated material. The enteric-coated tablet disclosed by the invention is simple in production process, universal in production equipment and low in cost, mainly overcomes the defect of large in-vivo absorption difference, and has a remarkable curative effect on treating neuritis.

1.The name of the design product: packaging box (Aleylinum methylcobalamin tablets). 2.The use of the design product: used for the outer packaging of medicines. 3.The design points of the design product: the combination of shape, pattern and color. 4.The picture or photo that best shows the design points: front view. 5.The design claimed contains color.

The invention discloses an anti-aging compound nutritional composition as well as a preparation method and application thereof, and belongs to the technical field of foods. The composition is prepared from the following components in unit dose: 150 to 250 mg of nicotinamide ribose, 10 to 30 mg of pyrroloquinoline quinone disodium salt, 100 to 200 mg of quercetin phospholipid complex, 300 to 500 [mu] g of (6S)-5-calcium methyltetrahydrofolate, 30 to 80 [mu] g of methyl cobalamin, 5 to 15 mg of pyridoxine hydrochloride, 50 to 100 mg of radix astragali seu hedysari extract, 50 to 100 mg of fructus lycii extract, 50 to 100 mg of rhizoma polygonati extract and auxiliary materials. Through the synergistic effect of the nutrients and the traditional Chinese medicine extracts, NAD < + > improvement, mitochondrial protection, oxidation resistance and energy metabolism regulation are achieved, and the nutrient composition has novelty, safety and industrial practicability and can be used for preparing anti-aging nutritional supplements or health-care foods.

This invention discloses a quantitative methylcobalamin capsule filling machine, relating to the field of methylcobalamin capsule processing technology. It includes a main support frame with a filling support frame fixedly connected to one side. A lower cover for a filling plate is rotatably connected above the filling support frame, and a upper cover for a filling plate is slidably connected above the lower cover. A ring-shaped array of outer filling tubes is fixedly installed inside the upper cover, and inner filling tubes corresponding to the number and position of the outer filling tubes are fixedly connected above the lower cover. The outer diameter of the inner filling tubes is equal to the inner diameter of the outer filling tubes. The height of the accommodating space between the inner and outer filling tubes is adjusted by the relative sliding between the upper and lower covers, thereby changing the amount of powder that can be filled each time. A drive motor rotates the filling plate, causing multiple filling tubes to pass sequentially under the inner rods of plungers at different heights, achieving graded compaction filling. This allows for precise control of the single filling amount, adapting to the production needs of different capsule specifications and avoiding uneven filling due to powder clumping or voids.

To provide a novel food and drink containing at least one cobalamin selected from the group consisting of cyanocobalamin, hydroxocobalamin, adenosylcobalamin, methylcobalamin, and sulfitecobalamin.SOLUTION: According to one aspect of the present invention, a bottled beverage is provided containing carnosine and at least one cobalamin selected from the group consisting of cyanocobalamin, hydroxocobalamin, adenosylcobalamin, methylcobalamin, and sulfitecobalamin, wherein the content of carnosine is 0.70 to 15 mg / mL, and the content of the at least one cobalamin is 0.005 to 1 μg / mL.SELECTED DRAWING: None

The invention provides a post-treatment purification process method of mecobalamin. The post-treatment purification process method comprises the following steps: (1) preparing a mecobalamin reaction solution; (2) filtering the mecobalamin reaction solution, and purifying through a high-pressure purification column to obtain a purified solution; (3) carrying out adsorption and desorption on the purified liquid through a resin column; (4) crystallizing and refining the desorption solution to obtain pure mecobalamin, and the like. By optimizing a mecobalamin post-treatment purification process, the impurity content is reduced, the yield of mecobalamin is improved, and the purification method is simple and convenient to operate and convenient for industrial production.

The purpose of the present invention is to provide a pharmaceutical composition for preventing or treating dementia, and a method for preventing or treating dementia.　The present invention pertains to: a pharmaceutical composition for preventing or treating dementia, the pharmaceutical composition comprising methylcobalamin as an active ingredient and being administered parenterally; a prevention or treatment method for preventing or treating dementia; and use.

The application discloses a method for accelerating straw degradation in a composting process, and belongs to the technical field of composting degradation. In order to solve the problem that straw degradation is slow in the composting process, the method comprises technical problems such as difficulty in degrading cellulose and semi-cellulose and complexity of a process. The method for accelerating straw degradation in the composting process comprises the following steps: adding methylcobalamin in a fermentation reaction in the composting process. The method realizes efficient and green utilization of straw, improves an ecological environment, and promotes environmental pollution treatment.

The application relates to a preparation method of a medicine composition for treating diabetic peripheral neuropathy, in particular to the following steps: mixing sodium citicoline, a binder, a filling agent, a disintegrating agent and a lubricant to obtain sodium citicoline mixed powder; mixing methylcobalamin, a binder, a filling agent, a disintegrating agent and a lubricant to obtain methylcobalamin mixed powder; compressing the sodium citicoline mixed powder and the methylcobalamin mixed powder on a double-layer tablet press to obtain double-layer double-release tablets; and coating the double-layer double-release tablets with light-shielding coating agent. The medicine composition for treating diabetic peripheral neuropathy prepared by the application is prepared into double-layer tablets by using sodium citicoline and methylcobalamin, which effectively guarantees the content uniformity of the medicinal components, the distribution uniformity in the tablets and the medicinal stability, reduces the medicine taking frequency and the auxiliary material intake amount of patients, and improves the use compliance of the patients.